United States · Platforms & data · Investing.com

Oppenheimer cuts Avalo Therapeutics price target on trial concerns

Published by Investing.com · United States 3 h ago

Read the full article on Investing.com Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.investing.com)

Also worth reading

Avidbank Holdings Non-GAAP EPS of $0.94 beats by $0.07, revenue of $30.4M beats by $1.14M

Sorry investors, but there’s no such thing as an early ‘Santa Claus rally.’ Here’s when the real gains typically happen.

The Motley Fool

Cameco vs. Centrus vs. BWX Technologies: Ranking the 3 Nuclear Stocks That Get Paid Before a Reactor Is Built.

Toncoin (TON) Price Prediction 2025, 2026, 2027-2030

NU Stock Suffers Worst Day On Record In Brazil Market Rout – Monness Crespi Initiates Coverage With ‘Buy’ Rating

Bill Gates warns of ‘winners and losers’ over next 20 years, even in ‘very best case’